Pushing Forward in Prostate Cancer Research

Almost everyone knows somebody living with prostate cancer.

The people we know are not just a statistic or a number. They are husbands, fathers, sons and brothers. They are families fighting to hang on to their dreams for the future. And that’s what we’re fighting for – aggressively building our prostate cancer research program to help advance new treatments for men who are running out of options.

“As with any cancer, there's a wide spectrum of clinical settings in prostate cancer and outcomes can vary between those with early versus later stage disease. Patients with advanced prostate cancer face limited options that's where Merck is committed to helping to address this public health issue.”
-Dr. Peter Kang, executive director, clinical research, Merck Research Laboratories

When prostate cancer is caught early, it generally has a better survival rate. But, for those men diagnosed with locally advanced or metastatic prostate cancer, the outcomes can be dramatically different. At Merck, we are focused on trying to do more for these men.

“Merck's prostate cancer research program, in collaboration with academia and other partners, is one of the most comprehensive programs in the industry,” says Dr. Kang. “We're working with a sense of urgency because prostate cancer affects many patients and their families, and they don't have time to wait.”

About Prostate Cancer

  • In the U.S., prostate cancer is the second leading cause of cancer death in men, behind lung cancer.
  • About 1 in 9 men will be diagnosed with prostate cancer during his lifetime.
  • The risk of prostate cancer is 74% higher in African Americans.
  • The average age at diagnosis is about 66.